Loading
A phase 3 trial of Fluciclovine F-18 in Glioma & glioblastoma, run by Nicole Hill, with a status the registry has not verified recently.
18F-Fluciclovine PET Imaging for Detecting High Grade Glioma Recurrence After Radiochemotherapy is a phase 3 interventional study registered as NCT05479136 by Nicole Hill, with 30 participants planned, started 2022-08-24 and due to reach its primary completion in 2023-12-31. Interventions recorded: PET imaging with 18F fluciclovine. Conditions recorded: Grade III or Grade IV Glioma.
Linked to the drug Fluciclovine F-18 because the registry names it among its interventions and Glioma & glioblastoma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fluciclovine F-18 and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/